SK Biopharmaceuticals Co., Ltd.
326030
Clasificación en acciones
#3827
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Precio por acción
$55.68
Capitalización bursátil
$4.36B
Cambio (1 día)
-1.47%
Cambio (1 año)
-26.34%
País
KR
Comercio SK Biopharmaceuticals Co., Ltd. (326030)
Categoría
Healthcare
Ingresos de SK Biopharmaceuticals Co., Ltd. (326030)
Ingresos en Jun 2026 TTM: $595.61M
Según los últimos informes financieros de SK Biopharmaceuticals Co., Ltd., los ingresos actuales de la empresa (TTM) son $595.61M. En 2024, la empresa obtuvo unos ingresos de $372.47M un aumento con respecto a los ingresos del año 2023, que fueron de $274.15M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de SK Biopharmaceuticals Co., Ltd. desde 2011 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $595.61M | 21.75% |
| 2025 | $489.22M | 31.34% |
| 2024 | $372.47M | 35.86% |
| 2023 | $274.15M | 40.53% |
| 2022 | $195.08M | -44.60% |
| 2021 | $352.13M | 1,370.42% |
| 2020 | $23.95M | -77.67% |
| 2019 | $107.25M | 10,769.59% |
| 2018 | $986.74K | -98.77% |
| 2017 | $80.05M | 7.33% |
| 2016 | $74.58M | 22.73% |
| 2015 | $60.77M | -8.20% |
| 2014 | $66.20M | 15.28% |
| 2013 | $57.42M | 18.01% |
| 2012 | $48.66M | 49.86% |
| 2011 | $32.47M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 2,019.55% |
US
|
|
| $2.23B | 274.07% |
US
|
|
| $15.74B | 2,543.39% |
AU
|
|
| $6.02B | 910.94% |
NL
|
|
| - | - |
CH
|
